<!DOCTYPE html><html class="" lang="en"><head>
<!-- REQUIRED META INFORMATION -->
<meta charset="UTF-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
<meta name="viewport" content="width=device-width, initial-scale=1">

<meta name="DCTERMS:contentOwner" content="TNeville">
<meta name="DCTERMS:contentOffice" content="DCRDP:ODP:OMP">

<meta name="DCTERMS:coder" content="^ORDP Webmaster">
<meta name="DCTERMS:coderOffice" content="DCRDP:ODEPPIN:OPPS">

<meta name="description" content="9.00-Endocrine-Adult">
<meta name="DCTERMS:dateCertified" content="2019-11-25">
 
<!-- DOCUMENT TITLE -->
<title>9.00 - Endocrine - Adult | Disability | SSA</title>
 
    <!-- STYLES -->
<link rel="stylesheet" href="/framework/css/ssa.firefly.css">

<!-- SCRIPTS -->
<script type="text/javascript" async="" src="https://www.googletagmanager.com/gtm.js?id=GTM-TL5XBDT&amp;gtm=4e5b50"></script><script async="" src="https://www.googletagmanager.com/gtm.js?id=GTM-5GQXH7Q"></script><script src="/framework/js/ssa.firefly.head.js"></script>


<script>(window.BOOMR_mq=window.BOOMR_mq||[]).push(["addVar",{"rua.upush":"false","rua.cpush":"false","rua.upre":"false","rua.cpre":"false","rua.uprl":"false","rua.cprl":"false","rua.cprf":"false","rua.trans":"","rua.cook":"false","rua.ims":"false","rua.ufprl":"false","rua.cfprl":"false","rua.isuxp":"false","rua.texp":"norulematch","rua.ceh":"false","rua.ueh":"false","rua.ieh.st":"0"}]);</script>
                              <script>!function(e){var n="https://s.go-mpulse.net/boomerang/";if("False"=="True")e.BOOMR_config=e.BOOMR_config||{},e.BOOMR_config.PageParams=e.BOOMR_config.PageParams||{},e.BOOMR_config.PageParams.pci=!0,n="https://s2.go-mpulse.net/boomerang/";if(window.BOOMR_API_key="LERZW-HECFS-R8H4E-23UQ7-ERMQB",function(){function e(){if(!o){var e=document.createElement("script");e.id="boomr-scr-as",e.src=window.BOOMR.url,e.async=!0,i.parentNode.appendChild(e),o=!0}}function t(e){o=!0;var n,t,a,r,d=document,O=window;if(window.BOOMR.snippetMethod=e?"if":"i",t=function(e,n){var t=d.createElement("script");t.id=n||"boomr-if-as",t.src=window.BOOMR.url,BOOMR_lstart=(new Date).getTime(),e=e||d.body,e.appendChild(t)},!window.addEventListener&&window.attachEvent&&navigator.userAgent.match(/MSIE [67]\./))return window.BOOMR.snippetMethod="s",void t(i.parentNode,"boomr-async");a=document.createElement("IFRAME"),a.src="about:blank",a.title="",a.role="presentation",a.loading="eager",r=(a.frameElement||a).style,r.width=0,r.height=0,r.border=0,r.display="none",i.parentNode.appendChild(a);try{O=a.contentWindow,d=O.document.open()}catch(_){n=document.domain,a.src="javascript:var d=document.open();d.domain='"+n+"';void(0);",O=a.contentWindow,d=O.document.open()}if(n)d._boomrl=function(){this.domain=n,t()},d.write("<bo"+"dy onload='document._boomrl();'>");else if(O._boomrl=function(){t()},O.addEventListener)O.addEventListener("load",O._boomrl,!1);else if(O.attachEvent)O.attachEvent("onload",O._boomrl);d.close()}function a(e){window.BOOMR_onload=e&&e.timeStamp||(new Date).getTime()}if(!window.BOOMR||!window.BOOMR.version&&!window.BOOMR.snippetExecuted){window.BOOMR=window.BOOMR||{},window.BOOMR.snippetStart=(new Date).getTime(),window.BOOMR.snippetExecuted=!0,window.BOOMR.snippetVersion=12,window.BOOMR.url=n+"LERZW-HECFS-R8H4E-23UQ7-ERMQB";var i=document.currentScript||document.getElementsByTagName("script")[0],o=!1,r=document.createElement("link");if(r.relList&&"function"==typeof r.relList.supports&&r.relList.supports("preload")&&"as"in r)window.BOOMR.snippetMethod="p",r.href=window.BOOMR.url,r.rel="preload",r.as="script",r.addEventListener("load",e),r.addEventListener("error",function(){t(!0)}),setTimeout(function(){if(!o)t(!0)},3e3),BOOMR_lstart=(new Date).getTime(),i.parentNode.appendChild(r);else t(!1);if(window.addEventListener)window.addEventListener("load",a,!1);else if(window.attachEvent)window.attachEvent("onload",a)}}(),"".length>0)if(e&&"performance"in e&&e.performance&&"function"==typeof e.performance.setResourceTimingBufferSize)e.performance.setResourceTimingBufferSize();!function(){if(BOOMR=e.BOOMR||{},BOOMR.plugins=BOOMR.plugins||{},!BOOMR.plugins.AK){var n=""=="true"?1:0,t="cookiepresent",a="im6jsaqxzhbro2ioay2q-f-9bf03d02e-clientnsv4-s.akamaihd.net",i="false"=="true"?2:1,o={"ak.v":"39","ak.cp":"1204614","ak.ai":parseInt("728289",10),"ak.ol":"0","ak.cr":24,"ak.ipv":4,"ak.proto":"h2","ak.rid":"ca16dee","ak.r":39734,"ak.a2":n,"ak.m":"dsca","ak.n":"essl","ak.bpcip":"67.60.153.0","ak.cport":51130,"ak.gh":"23.201.194.23","ak.quicv":"","ak.tlsv":"tls1.3","ak.0rtt":"","ak.0rtt.ed":"","ak.csrc":"-","ak.acc":"","ak.t":"1762526773","ak.ak":"hOBiQwZUYzCg5VSAfCLimQ==YGrnh7Y/SQnZ8i83fvXku6GzM+VNqdYoOJtC5K4mgwKwfF4lOc66SQ7ttv6fa9QgpugZw2E+Ti0e/PcCJm0hQBtsM2Y8tsxk8+lLLxsZGi2JrlWED5+ACIMtDCfgrXFwKvHj39aHSseklwS6Ijjb3MjmQkJZ/Wi/6tQkLPS9XPVqhnhpHFXhjMsDHSAX3sX5qG4sXZIuyRlWq0Z99Sog4TMsiWRkEm+LDvXGUHilW9MdnuipWvVcd+XTIZU4bL+UD/y6zDc2IdpHVxyZEcVzsZyZMT5Ze/lBBMxuyRosfmQyA1Dj3wE458jSEmxgFw7oGqLGptsqW8YHWdxz6cUb2oTiVlbI5E2UVK5Qy9VnFtovZdSS9Se7BYTPEjmMxF/qT8VhhIdG+i9pL9S3rd6xyTtLG4rZP/Uw/KkqUClBc+0=","ak.pv":"120","ak.dpoabenc":"","ak.tf":i};if(""!==t)o["ak.ruds"]=t;var r={i:!1,av:function(n){var t="http.initiator";if(n&&(!n[t]||"spa_hard"===n[t]))o["ak.feo"]=void 0!==e.aFeoApplied?1:0,BOOMR.addVar(o)},rv:function(){var e=["ak.bpcip","ak.cport","ak.cr","ak.csrc","ak.gh","ak.ipv","ak.m","ak.n","ak.ol","ak.proto","ak.quicv","ak.tlsv","ak.0rtt","ak.0rtt.ed","ak.r","ak.acc","ak.t","ak.tf"];BOOMR.removeVar(e)}};BOOMR.plugins.AK={akVars:o,akDNSPreFetchDomain:a,init:function(){if(!r.i){var e=BOOMR.subscribe;e("before_beacon",r.av,null,null),e("onbeacon",r.rv,null,null),r.i=!0}return this},is_complete:function(){return!0}}}}()}(window);</script><link href="https://s.go-mpulse.net/boomerang/LERZW-HECFS-R8H4E-23UQ7-ERMQB" rel="preload" as="script"><style>@font-face{font-family:"Public Sans Web";src:url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Light.woff2) format("woff2"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Light.woff) format("woff"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Light.ttf) format("truetype");font-weight:300;font-style:normal;font-display:swap}@font-face{font-family:"Public Sans Web";src:url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Regular.woff2) format("woff2"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Regular.woff) format("woff"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Regular.ttf) format("truetype");font-weight:400;font-style:normal;font-display:swap}@font-face{font-family:"Public Sans Web";src:url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-SemiBold.woff2) format("woff2"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-SemiBold.woff) format("woff"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-SemiBold.ttf) format("truetype");font-weight:600;font-style:normal;font-display:swap}@font-face{font-family:"Public Sans Web";src:url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Bold.woff2) format("woff2"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Bold.woff) format("woff"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Bold.ttf) format("truetype");font-weight:700;font-style:normal;font-display:swap}@font-face{font-family:"Public Sans Web";src:url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-ExtraBold.woff2) format("woff2"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-ExtraBold.woff) format("woff"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-ExtraBold.ttf) format("truetype");font-weight:800;font-style:normal;font-display:swap}</style><meta property="og:site_name" content="Social Security"><meta property="og:type" content="website"><meta property="og:url" content="https://www.ssa.gov/disability/professionals/bluebook/9.00-Endocrine-Adult.htm"><meta property="og:title" content="9.00 - Endocrine - Adult | Disability | SSA"><meta property="og:description" content="9.00-Endocrine-Adult"><meta property="og:image:url" content="https://www.ssa.gov/themes/custom/ssa_core/logo.svg"><meta property="og:image:secure_url" content="https://www.ssa.gov/themes/custom/ssa_core/logo.svg"><meta property="og:image:alt" content="U.S. Social Security Administration"><meta property="og:locale" content="en_US"><meta property="og:locale:alternate" content="es_ES"><script id="boomr-scr-as" src="https://s.go-mpulse.net/boomerang/LERZW-HECFS-R8H4E-23UQ7-ERMQB" async=""></script></head>

<body style="margin: 0px;">
  <!-- BANNER -->
  <aside class="accessibility" id="accessibility"><a href="#content" id="skip-navigation">Skip to main content</a></aside>
<!-- WCMS SITE ALERT (EMERGENCY) -->
<div class="wsa" aria-label="Site Alert" data-type="emergency">
  <div class="wsag">
    <svg focusable="false" height="26" width="26" viewBox="0 0 20 20" aria-hidden="true">
      <path fill="#FFFFFF" fill-rule="evenodd" stroke-width="0" d="M10.8,15h-1.7v-1.7h1.7v1.7ZM10.8,11.7h-1.7v-4.9h1.7v4.9Z" vector-effect="non-scaling-stroke"></path>
      <path fill="#1C1D1F" fill-rule="evenodd" stroke-width="0" d="M.8,17.5h18.3L10,1.7.8,17.5ZM10.8,15h-1.7v-1.7h1.7v1.7ZM10.8,11.7h-1.7v-4.9h1.7v4.9h0Z" vector-effect="non-scaling-stroke"></path>
    </svg>
    <div>
      <a href="/myaccount/"><u>Social Security and SSI Payments will Continue during the Government Shutdown.  Visit my Social Security for Online Services.</u></a>
    </div>
  </div>
</div>
<!-- WCMS SITE ALERT (INFORMATION) -->
<div class="wsa" aria-label="Site Alert" data-type="information">
  <div class="wsag">
    <svg focusable="false" height="26" width="26" viewBox="0 0 20 20" aria-hidden="true">
      <path fill="#1C1D1F" fill-rule="evenodd" stroke-width="0" d="M10,1.7C5.4,1.7,1.7,5.4,1.7,10s3.7,8.3,8.3,8.3,8.3-3.7,8.3-8.3S14.6,1.7,10,1.7ZM9.2,7.5v-1.7h1.7v1.7h-1.7ZM9.2,9.2v5h1.7v-5h-1.7Z" vector-effect="non-scaling-stroke"></path>
      <path fill="#FFFFFF" fill-rule="evenodd" stroke-width="0" d="M10.8,7.5h-1.7v-1.7h1.7v1.7Z" vector-effect="non-scaling-stroke"></path>
      <path fill="#FFFFFF" fill-rule="evenodd" stroke-width="0" d="M10.8,14.2h-1.7v-5h1.7v5Z" vector-effect="non-scaling-stroke"></path>
    </svg>
    <div>
      <a href="https://www.ssa.gov/manage-benefits/get-benefit-letter"><u>Get a benefit verification letter.</u></a>
    </div>
  </div>
</div>
<ssa-header class="print-dn"></ssa-header><script src="https://www.ssa.gov/legacy/components/dist/ssa-header.js"></script>
  <!-- MAIN CONTENT -->
  <main class="content" id="content" role="main">
    <!-- TITLE BAR -->
    <section class="bg-ivory-200">
      <!-- WRAPPER -->
      <div class="py2 wrapper">
        <h2 class="fw4 ma0">Medical/Professional Relations</h2>
     </div>
    </section>

    <!-- WRAPPER -->
    <section class="wrapper">
    
    <!--GRID-->
<div class="grid">
	
<!-- FIRST COLUMN -->
<article class="cell w-100 m-w-100">
	
<!-- BREADCRUMBS -->
<nav class="breadcrumbs fs1" aria-label="Breadcrumbs">
  <ol>
    <li><a href="https://www.ssa.gov">SSA Home</a></li>
	<li><a href="https://www.ssa.gov/disability">Disability</a></li>
	<li><a href="../index.htm">Medical/Professional Relations</a></li>
	<li><a href="index.htm">Disability Evaluation Under Social Security</a></li>
	<li><a href="AdultListings.htm">Listing of Impairments - Adult Listings (Part A)</a></li> 
    <li aria-current="page">9.00 Endocrine Disorders - Adult</li>
  </ol>
</nav>
</article><!--END FIRST COLUMN-->

<!-- FIRST COLUMN -->
<article class="cell w-100 m-w-20">


<p class="js-toggle"><a href="AdultListings.htm">Adult Listings (Part A)</a></p>
<p class="js-toggle"><a href="ChildhoodListings.htm">Childhood Listings (Part B)</a></p>
<p class="js-toggle"><a href="general-info.htm">General Information</a></p>
<p class="js-toggle"><a href="evidentiary.htm">Evidentiary Requirements</a></p>
<p class="js-toggle"><a href="listing-impairments.htm">Listing of Impairments (overview) </a></p>

<p class="js-toggle"><a href="revisions-rules.html">Revisions to Rules Regarding the Evaluation of Medical Evidence</a></p>
                          </article><!-- END FIRST COLUMN-->

<!--SECOND COLUMN-->
<article class="cell w-100 m-w-80">

      <h2><span><b> Disability Evaluation Under Social Security<br>
        <br>
        9.00 Endocrine Disorders - Adult<br>
        &nbsp;</b></span></h2>

<p id="9_00"><u><b>Section 9.00 Endocrine Disorders</b></u></p>
 
<p id="9_00A">A. <u>What is an endocrine disorder?</u></p>
          
            <p align="left">An endocrine disorder is a medical condition that causes a hormonal imbalance.&nbsp;  
                When an endocrine gland functions abnormally, producing either too much  of a specific hormone (hyperfunction) or too little (hypofunction), the hormonal imbalance can cause various complications in the body.&nbsp; 
                The major glands of the endocrine system are the pituitary, thyroid, parathyroid, adrenal, and pancreas.</p>
           
            <p align="left" id="9_00B">B. <u>How do we evaluate the effects of endocrine disorders?</u>&nbsp;                 We  evaluate impairments that result from endocrine disorders under the listings for other body systems.&nbsp; For example:</p>
         
            
              <p align="left" id="9_00B1">1. <u>Pituitary gland disorders</u> can disrupt hormone production and normal functioning in other endocrine glands and in many body systems.&nbsp; 
                The effects of pituitary gland disorders vary depending on which hormones are involved.&nbsp; For example, when pituitary hypofunction affects water and electrolyte balance in the kidney and leads to diabetes insipidus, 
                we evaluate the effects of recurrent dehydration under <a href="6.00-Genitourinary-Adult.htm#6_00" title="6.00 Genitourinary Disorders Page, Section 6.00" target="_blank">6.00</a>.</p>
              <p align="left" id="9_00B2">2. <u>Thyroid gland disorders</u> affect the sympathetic nervous system and normal metabolism.&nbsp; 
                We evaluate thyroid-related changes in blood pressure and heart rate that cause arrhythmias or other cardiac dysfunction under <a href="4.00-Cardiovascular-Adult.htm#4_00" title="4.00 Cardiovascular System Page, Section 4.00" target="_blank">4.00</a>; 
                thyroid-related weight loss under <a href="5.00-Digestive-Adult.htm#5_00" title="5.00 Digestive System Page, Section 5.00" target="_blank">5.00</a>; 
                hypertensive cerebrovascular accidents (strokes) under <a href="11.00-Neurological-Adult.htm#11_00" title="11.00 Neurological Disorders Page, Section 11.00" target="_blank">11.00</a>; 
                and cognitive limitations, mood disorders, and anxiety under <a href="12.00-MentalDisorders-Adult.htm#12_00" title="12.00 Neurological Disorders Page, Section 12.00" target="_blank">12.00</a>.</p>
              <p align="left" id="9_00B3">3. <u>Parathyroid gland disorders</u> affect calcium levels in bone, blood, nerves, muscle, and other body  tissues.&nbsp; 
                We evaluate parathyroid-related osteoporosis and fractures under <a href="1.00-Musculoskeletal-Adult.htm#1_00" title="1.00 Musculoskeletal System Page, Section 1.00" target="_blank">1.00</a>; 
                abnormally elevated calcium levels in  the blood (hypercalcemia) that lead to cataracts under <a href="2.00-SpecialSensesandSpeech-Adult.htm#2_00" title="2.00 Special Senses and Speech Page, Section 2.00" target="_blank">2.00</a>; 
                kidney failure under <a href="6.00-Genitourinary-Adult.htm#6_00" title="6.00 Genitourinary Disorders Page, Section 6.00" target="_blank">6.00</a>; 
                and recurrent abnormally low blood calcium levels (hypocalcemia) that lead to increased excitability of nerves and muscles, such as tetany and muscle spasms, 
                under <a href="11.00-Neurological-Adult.htm#11_00" title="11.00 Neurological Disorders Page, Section 11.00" target="_blank">11.00</a>.</p>
              <p align="left" id="9_00B4">4. <u>Adrenal gland disorders</u> affect bone calcium levels, blood pressure, metabolism, and mental status.&nbsp; 
                We evaluate adrenal-related osteoporosis with fractures that compromises the ability to walk or to use the upper extremities under <a href="1.00-Musculoskeletal-Adult.htm#1_00" title="1.00 Musculoskeletal System Page, Section 1.00" target="_blank">1.00</a>;
    adrenal-related hypertension that worsens heart failure or causes recurrent arrhythmias under <a href="4.00-Cardiovascular-Adult.htm#4_00" title="4.00 Cardiovascular System Page, Section 4.00" target="_blank">4.00</a>; 
    adrenal-related weight loss under <a href="5.00-Digestive-Adult.htm#5_00" title="5.00 Digestive System Page, Section 5.00" target="_blank">5.00</a>; 
    and mood disorders under <a href="12.00-MentalDisorders-Adult.htm#12_00" title="12.00 Neurological Disorders Page, Section 12.00" target="_blank">12.00</a>.
</p>
              <p align="left" id="9_00B5">5. <u>Diabetes mellitus and other  pancreatic gland disorders</u> disrupt the production of several hormones, including insulin, that regulate metabolism and digestion.
                &nbsp; Insulin is essential to the absorption of glucose from the bloodstream into body cells for conversion into cellular energy.&nbsp; The most common pancreatic gland  disorder is <u>diabetes mellitus</u> (DM).&nbsp; 
                There are two major types of DM:&nbsp; type 1 and type 2.&nbsp; Both type 1 and type 2 DM are chronic disorders that can have serious disabling  complications that meet the duration requirement.&nbsp; 
                Type 1 DM--previously known as “juvenile  diabetes” or “insulin-dependent diabetes mellitus” 
                (IDDM)--is an absolute  deficiency of insulin production that commonly begins in childhood and continues throughout adulthood.&nbsp;  Treatment of type 1 DM always requires lifelong daily insulin. 
                &nbsp;With type 2 DM--previously known as  “adult-onset diabetes mellitus” or “non-insulin-dependent diabetes mellitus”  (NIDDM)--the body’s cells resist the effects of insulin, 
                impairing glucose absorption and metabolism.&nbsp; Treatment of  type 2 DM generally requires lifestyle changes, such as increased exercise and dietary modification, 
                and sometimes insulin in addition to other medications.&nbsp; While both type 1 and type 2 DM are usually  controlled, some persons do not achieve good control for a variety of reasons including, but not limited to, 
                hypoglycemia unawareness, other disorders that  can affect blood glucose levels, inability to manage DM due to a mental  disorder, or inadequate treatment.</p>
              
                <p align="left" id="9_00B1a">a. <u>Hyperglycemia.</u>&nbsp; Both types of DM cause hyperglycemia, which is an abnormally high level of blood glucose that may produce acute and long-term complications.
                &nbsp; Acute complications of hyperglycemia include diabetic ketoacidosis.&nbsp; Long-term complications of chronic hyperglycemia include many conditions affecting various body systems.</p>
              
                <p align="left" id="9_00B1ai">(i) <u>Diabetic ketoacidosis (DKA).</u>&nbsp; 
                DKA is an acute, potentially life-threatening complication of DM in which the chemical balance of the body becomes dangerously hyperglycemic and acidic.&nbsp; 
                It results from a severe insulin deficiency, which  can occur due to missed or inadequate daily insulin therapy or in association  with an acute illness.&nbsp; 
                It usually requires hospital treatment to correct the acute complications of dehydration,  electrolyte imbalance, and insulin deficiency.&nbsp;  
                You may have serious complications resulting from your treatment, which  we evaluate under the affected body system.&nbsp;  
                For example, we evaluate cardiac arrhythmias under <a href="4.00-Cardiovascular-Adult.htm#4_00" title="4.00 Cardiovascular System Page, Section 4.00" target="_blank">4.00</a>, 
                intestinal necrosis under <a href="5.00-Digestive-Adult.htm#5_00" title="5.00 Digestive System Page, Section 5.00" target="_blank">5.00</a>, 
                and cerebral edema and seizures under <a href="11.00-Neurological-Adult.htm#11_00" title="11.00 Neurological Disorders Page, Section 11.00" target="_blank">11.00</a>.&nbsp; 
                Recurrent episodes of DKA may result from mood or eating disorders, which we evaluate under <a href="12.00-MentalDisorders-Adult.htm#12_00" title="12.00 Neurological Disorders Page, Section 12.00" target="_blank">12.00</a>.</p>
              <p align="left" id="9_00B1aii">(ii) <u>Chronic hyperglycemia.</u>&nbsp; Chronic hyperglycemia, which is longstanding  abnormally high levels of blood glucose, 
                leads to long-term diabetic complications by disrupting nerve and blood vessel functioning.&nbsp; This disruption can have many different  effects in other body systems.&nbsp; 
                For example, we evaluate diabetic peripheral neurovascular disease that leads to gangrene and subsequent amputation of an extremity under <a href="1.00-Musculoskeletal-Adult.htm#1_00" title="1.00 Musculoskeletal System Page, Section 1.00" target="_blank">1.00</a>; 
                diabetic retinopathy under <a href="2.00-SpecialSensesandSpeech-Adult.htm#2_00" title="2.00 Special Senses and Speech Page, Section 2.00" target="_blank">2.00</a>; 
                coronary artery disease and peripheral vascular disease under <a href="4.00-Cardiovascular-Adult.htm#4_00" title="4.00 Cardiovascular System Page, Section 4.00" target="_blank">4.00</a>; 
                diabetic gastroparesis that results in abnormal gastrointestinal motility under <a href="5.00-Digestive-Adult.htm#5_00" title="5.00 Digestive System Page, Section 5.00" target="_blank">5.00</a>; 
                diabetic nephropathy under <a href="6.00-Genitourinary-Adult.htm#6_00" title="6.00 Genitourinary Disorders Page, Section 6.00" target="_blank">6.00</a>; 
                poorly healing bacterial and fungal skin  infections under <a href="8.00-Skin-Adult.htm#8_00" title="8.00 Cardiovascular System Page, Section 8.00" target="_blank">8.00</a>; 
                diabetic peripheral and sensory neuropathies under <a href="11.00-Neurological-Adult.htm#11_00" title="11.00 Neurological Disorders Page, Section 11.00" target="_blank">11.00</a>; 
                and cognitive impairments, depression, and anxiety under <a href="12.00-MentalDisorders-Adult.htm#12_00" title="12.00 Neurological Disorders Page, Section 12.00" target="_blank">12.00</a>.</p>
              
              
              <p align="left" id="9_00B1b">b. <u>Hypoglycemia.</u>&nbsp; Persons with DM may experience episodes of hypoglycemia, which is an abnormally low level of blood glucose.&nbsp; 
                Most adults recognize the symptoms of hypoglycemia and reverse them by consuming substances containing glucose; however, some do not take this step because of hypoglycemia unawareness.&nbsp; 
                Severe hypoglycemia can lead to complications, including seizures or loss of consciousness, 
                which we evaluate under <a href="11.00-Neurological-Adult.htm#11_00" title="11.00 Neurological Disorders Page, Section 11.00" target="_blank">11.00</a>, 
                or altered mental status and cognitive deficits, which we evaluate under <a href="12.00-MentalDisorders-Adult.htm#12_00" title="12.00 Neurological Disorders Page, Section 12.00" target="_blank">12.00</a>.</p>
                        
            <p align="left" id="9_00C">C. <u>How do we evaluate endocrine disorders that do not have effects that meet or medically equal the criteria of any listing in other body systems?</u>&nbsp; 
                If your impairment(s) does not meet or  medically equal a listing in another body system, you may or may not have the  residual functional capacity to engage in substantial gainful activity.&nbsp; 
                In this situation, we proceed to the fourth  and, if necessary, 
                the fifth steps of the sequential evaluation process in §§<a href="https://www.ssa.gov/OP_Home/cfr20/404/404-1520.htm" target="_blank" title="Code of Federal Regulations section 404.1520">404.1520</a> 
                and <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0920.htm" target="_blank" title="Code of Federal Regulations section 416.920">416.920</a>.&nbsp; 
                When we decide whether you continue to be disabled, we use the rules in §§<a href="https://www.ssa.gov/OP_Home/cfr20/404/404-1594.htm" target="_blank" title="Code of Federal Regulations section 404.1594">404.1594</a>,
                <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0994.htm" target="_blank" title="Code of Federal Regulations section 416.994">416.994</a>, 
                and <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0994a.htm" target="_blank" title="Code of Federal Regulations section 416.994, Subsection a">416.994a</a>.
</p>

</article><!-- END SECOND COLUMN -->

</div><!-- END GRID-->

    </section>
  </main>
  <!-- FOOTER -->
  <ssa-footer class="print-dn"></ssa-footer><script src="https://www.ssa.gov/legacy/components/dist/ssa-footer.js"></script>
  <!-- SCRIPTS -->
  <script src="/framework/js/ssa.firefly.body.js"></script><a class="js-btt" href="#" title="Back to Top"></a>


</body></html>